Verteporfin Dosage

This dosage information may not include all the information needed to use Verteporfin safely and effectively. See additional information for Verteporfin.

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Geriatric Dose for:

Additional dosage information:

Usual Adult Dose for Macular Degeneration

Subfoveal choroidal neovascularization: 6 mg/m2 body surface area intravenously over 10 minutes, once. The drug is photoactivated by 83 seconds of laser light administration (689 nm) commencing 15 minutes after start of the infusion.

Bilateral lesions in patients who have never undergone verteporfin therapy: 6 mg/m2 body surface area intravenously over 10 minutes, once. The drug is photoactivated by 83 seconds of laser light administration (689 nm) commencing 15 minutes after start of the infusion. The most aggressive lesion should be treated first. If, after the first treatment, an acceptable safety profile is identified, treatment of the second eye can commence no sooner than one week following the first course.

Bilateral lesions in patients who have undergone previous verteporfin therapy: 6 mg/m2 body surface area intravenously over 10 minutes, once. The drug is photoactivated by 83 seconds of laser light administration (689 nm) commencing 15 minutes after start of the infusion. If the patient showed an acceptable safety profile following the first course of verteporfin therapy then both eyes may be treated concurrently after a single administration of verteporfin. The more aggressive lesion should be treated first 15 minutes after the start of the verteporfin infusion. The treatment of the second eye should be initiated immediately at the end of the light treatment of the first eye using the same light dose and intensity as for the first eye. The treatment of the second eye should start no later than 20 minutes after the start of the verteporfin infusion.

Patients may be retreated in 3 months, if necessary.

Usual Geriatric Dose for Macular Degeneration

Subfoveal choroidal neovascularization: 6 mg/m2 body surface area intravenously over 10 minutes, once. The drug is photoactivated by 83 seconds of laser light administration (689 nm) commencing 15 minutes after start of the infusion.

Bilateral lesions in patients who have never undergone verteporfin therapy: 6 mg/m2 body surface area intravenously over 10 minutes, once. The drug is photoactivated by 83 seconds of laser light administration (689 nm) commencing 15 minutes after start of the infusion. The most aggressive lesion should be treated first. If, after the first treatment, an acceptable safety profile is identified, treatment of the second eye can commence no sooner than one week following the first course.

Bilateral lesions in patients who have undergone previous verteporfin therapy: 6 mg/m2 body surface area intravenously over 10 minutes, once. The drug is photoactivated by 83 seconds of laser light administration (689 nm) commencing 15 minutes after start of the infusion. If the patient showed an acceptable safety profile following the first course of verteporfin therapy then both eyes may be treated concurrently after a single administration of verteporfin. The more aggressive lesion should be treated first 15 minutes after the start of the verteporfin infusion. The treatment of the second eye should be initiated immediately at the end of the light treatment of the first eye using the same light dose and intensity as for the first eye. The treatment of the second eye should start no later than 20 minutes after the start of the verteporfin infusion.

A decreased treatment effect has been reported in elderly patients

Patients may be retreated in 3 months, if necessary.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

There are no clinical data on the safety of verteporfin in patients with hepatic impairment.

Precautions

Verteporfin is contraindicated in patients with porphyria.

Patients must avoid exposing their skin or eyes to direct sunlight or bright indoor lights (such as tanning salons, halogen lights, or high power surgical and dental lighting) for 5 days after receiving verteporfin. UV sunscreens do not protect against the photosensitivity reaction. Ambient indoor lighting is acceptable and will help inactivate verteporfin.

Patients must avoid prolonged exposure to light from light-emitting medical devices, such as pulse oximeters, for up to 5 days following administration of verteporfin.

The largest arm vein possible should be used for injection. Small veins in the back of the hand should be avoided.

If extravasation occurs, the infusion should be stopped immediately and cold compresses should be applied. The area must be protected from direct light until swelling and discoloration have resolved in order to prevent potentially severe local burns.

If the patient requires surgery within 48 hours of receiving verteporfin, internal tissues should be protected from intense light as much as possible.

If a severe decrease in vision of 4 lines or more occurs within 1 week of treatment, patients should not be retreated until their vision recovers to pretreatment levels and risk-benefit has been evaluated.

Use of incompatible lasers that do not provide the required characteristics of light (689 nm) for photoactivation may result in incomplete treatment, overtreatment, or damage to surrounding normal tissues.

Persons preparing and handling verteporfin should avoid skin and eye contact. Use of eye protection and rubber gloves are advised by the manufacturer. If exposed, they should avoid sunlight and bright light to prevent photosensitivity reactions.

There are no clinical data on the safety of verteporfin in patients with hepatic impairment or in anesthetized patients.

Safety and efficacy have not been established in children less than 18 years.

Dialysis

Data not available

Hide
(web4)